Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics made significant strides in its cell therapy programs, enrolling the first patient in its CHM CDH17 Phase 1/2 trial targeting colorectal and other cancers. The company is also collaborating with partners to expand patient access and manufacturing capabilities. Additionally, Chimeric secured $5 million in capital commitments, signaling strong investor confidence.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.